Journal article
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT.
- Gagelmann N University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Eikema DJ EBMT Statistical Unit and Data Office Leiden, Leiden, The Netherlands.
- de Wreede LC Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
- Rambaldi A Department of Oncology-Hematology, University of Milan and Azienda Socio Sanitaria Territoriale, Papa Giovanni XXIII, Bergamo, Italy.
- Iacobelli S EBMT Statistical Unit and Data Office Leiden, Leiden, The Netherlands.
- Koster L EBMT Statistical Unit and Data Office Leiden, Leiden, The Netherlands.
- Caillot D Hôpital d'Enfants Dijon, Dijon, France.
- Blaise D Institut Paoli-Calmettes, Marseille, France.
- Remémyi P Dél-pesti Centrumkórház-Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary.
- Bulabois CE CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France.
- Passweg J University Hospital Basel, Basel, Switzerland.
- Leleu X Hopital La Miletrie, Poitiers, France.
- Zver S University Med. Center Ljubljana, Ljubljana, Slovenia.
- Kobbe G Department of Hematology, University Hospital, Heinrich Heine University, Düsseldorf, Germany.
- Ljungman P Karolinska University Hospital, Stockholm, Sweden.
- Chevallier P CHU Nantes, Nantes, France.
- Ringhoffer M Klinikum Karlsruhe gGmbH, Karlsruhe, Germany.
- Martin M Leicester Royal Infirmary, Leicester, UK.
- Salmenniemi U Turku University Hospital, Turku, Finland.
- Poiré X Cliniques Universitaires St. Luc, Brussels, Belgium.
- Lenhoff S Skanes University Hospital, Lund, Sweden.
- Pioltelli P Ospedale San Gerardo, Monza, Italy.
- Mordini N Az. Ospedaliera S. Croce e Carle, Cuneo, Italy.
- Delforge M University Hospital Gasthuisberg, Leuven, Belgium.
- Garderet L Hôpital Saint Antoine, Paris, France.
- Schönland S University of Heidelberg, Heidelberg, Germany.
- Yakoub-Agha I CHU de Lille, LIRIC, INSERM U995, Université de Lille, 59000, Lille, France.
- Kröger N University Medical Center Hamburg-Eppendorf, Hamburg, Germany. nkroeger@uke.uni-hamburg.de.
- 2020-07-26
Published in:
- Bone marrow transplantation. - 2020
English
We analyzed newly diagnosed multiple myeloma patients with del(17p) and/or t(4;14) undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation. 623 patients underwent either auto (n = 446), auto-auto (n = 105), or auto-allo (n = 72) between 2000 and 2015. 46% of patients had t(4;14), 45% had del(17p) while 9% were reported having both abnormalities. Five-year overall survival (OS) was 51% (95% confidence interval [CI], 45-58%) for single auto, 60% (95% CI, 49-72%) for auto-auto, and 67% (95% CI, 53-80%) for auto-allo (p = 0.187). Five-year progression-free survival (PFS) was 17% (95% CI, 12-22%), 33% (95% CI, 22-43%), and 34% (95% CI, 21-38%; p = 0.048). Five-year relapse rate was 82, 63, and 56%, while non-relapse mortality was 1, 4, and 10%. In multivariable analysis, in t(4;14) with single auto as reference, auto-auto (hazard ratio [HR], 0.44; p = 0.007) and auto-allo (HR, 0.45; p = 0.018) were associated with better PFS. In terms of t(4;14) and OS, auto-auto appeared to improve outcome compared with single auto (HR, 0.49; p = 0.096). In del(17p), outcome in PFS was similar between single auto and auto-auto, while auto-allo appeared to improve PFS (HR, 0.65; p = 0.097). No significant difference in OS was identified between the groups in patients with del(17p).
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1038/s41409-020-01007-w
- PMID 32710010
- Persistent URL
- https://sonar.ch/global/documents/92632
Statistics
Document views: 17
File downloads: